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Abstract: Early detection (localized stage) of colon cancer is associated with a five-year survival rate of 91%. Only 39% of colon 
  cancers, however, are diagnosed at that early stage. Early and accurate diagnosis, therefore, constitutes a critical need and a decisive 
factor in the clinical treatment of colon cancer and its success. In this study, using supervised linear discriminant analysis, we have 
developed three diagnostic biomarker models that—based on global micro-RNA expression analysis of colonic tissue collected during 
surgery—can discriminate with a perfect accuracy between subjects with colon cancer (stages II–IV) and normal healthy subjects. We 
developed our three diagnostic biomarker models with 57 subjects [40 with colon cancer (stages II–IV) and 17 normal], and we vali-
dated them with 39 unknown (new and different) subjects [28 with colon cancer (stages II–IV) and 11 normal]. For all three diagnostic 
models, both the overall sensitivity and specificity were 100%. The nine most significant micro-RNAs identified, which comprise the 
input variables to the three linear discriminant functions, are associated with genes that regulate oncogenesis, and they play a paramount 
role in the development of colon cancer, as evidenced in the tumor tissue itself. This could have a significant impact in the fight against 
this disease, in that it may lead to the development of an early serum or blood diagnostic test based on the detection of those nine key 
micro-RNAs.
Keywords: colon cancer, ROC-supervised linear discriminant analysis, biomarkers, diagnostic biomarker models, global micro-RNA 
expression analysis, systems biologyNikas and Low
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Introduction
Colorectal cancer is the third most common type of 
cancer for both males and females. In 2010, there were 
an estimated 102,900 new cases of colon and 39,670 
cases of rectal cancer, and an estimated 51,370 deaths 
from colorectal cancer occurred.1,2 The five-year sur-
vival rate for those patients who are diagnosed at an 
early stage (localized stage—stage I or II) is 91%; 
however, only 39% of colorectal cancer patients are 
diagnosed at an early stage.1 If the colorectal cancer 
has spread to adjacent organs or lymph nodes, the 
five-year survival drops to 70%, and if it has spread 
to distant organs, the five-year survival is 11%.1 It 
follows, therefore, that early and accurate diagnos-
tic tests would have a significant impact in the fight 
against this disease by saving thousands of lives every 
year. Furthermore, if an early and accurate diagnostic 
test were based on serum or blood, then it would have 
additional significant advantages: it would be consid-
erably less invasive and expensive than colonoscopy, 
the current standard diagnostic procedure for colon 
cancer (CCA).
In this study, we analyzed the global micro-RNA 
(miRNA)  expression  data  of  colonic  tumor  and 
healthy tissue obtained during surgery from 96 sub-
jects [68 with CCA (stages II–IV) and 28 normal]. We 
developed three different and independent diagnostic 
biomarker  models  using  57  subjects  [40  with  CCA 
(stages II–IV) and 17 normal], and we validated all 
three of them with 39 unknown subjects [28 with CCA 
(stages II–IV) and 11 normal] that were new and dif-
ferent from those 57 subjects used in the development 
of the models. Our three diagnostic biomarker models 
were able to identify with a perfect accuracy (overall 
sensitivity: 100.00% and overall specificity: 100.00%) 
all 68   subjects with CCA and all 28 normal subjects.
Each of our three diagnostic biomarker models is a 
linear discriminant function of a number of miRNAs. 
Altogether,  nine  miRNAs  constitute  the  input  vari-
ables to all three diagnostic biomarker models, and 
they are deemed highly significant in the discrimina-
tion between healthy normal tissue and tumor tissue, as 
well as, therefore, in the development of colon cancer.
Materials and Methods
Data acquisition
We  used  the  normalized  miRNA  data  for  68  sub-
jects  with  CCA  (stages  II–IV)  (labeled  ‘pMMR’) 
and for 28 normal subjects by Sarver et al3 posted at 
the GEO (Gene Expression Omnibus) of the NCBI 
(National  Center  for  Biotechnology  Information) 
[ID: GSE18392].
Discovery and validation studies
Of the total 96 subjects, we randomly selected 57 
of them [40 with CCA (stages II–IV) and 17 normal 
(NRM)] for the development and training of the diag-
nostic biomarker models. The remaining 39 subjects 
[28 with CCA (stages II–IV) and 11 NRM] constituted 
the unknown subjects with which all diagnostic bio-
marker models were tested. This validation method 
provided  us  with  the  means  to  test  our  diagnostic 
biomarker models with 39 new and real unknowns 
that were different from the subjects used for—and, 
therefore,  completely  extraneous  to—the  develop-
ment and training of the models. The proportions of 
the stages (II-IV) in the total set of 68 CCA subjects 
were maintained in both the discovery and validation 
subsets of CCA subjects.
Statistical methods
In order to reduce the dimensionality of the data and 
zero in on those variables (miRNAs) that are most 
significant in the process that differentiates between 
normal healthy tissue and CCA tissue, we applied 
our bioinformatic methods that we have developed, 
presented, and explained in a great detail in our pre-
vious studies.4–7 Briefly, we performed ROC curve 
analysis on the entire data matrix, i.e., on all vari-
ables (735 miRNAs × 96 subjects) in order to assess 
the discriminating capability of all variables with 
respect to our two groups, namely, CCA and NRM. In 
the final round, we selected only those variables with 
an AUC $ 0.97. Twelve variables (miRNAs) ful-
filled this criterion, and they constituted the final 
pool of the most significant variables. We should 
point out that our method used in this study consti-
tutes a novel   linear discriminant analysis method, 
i.e., one that is carefully supervised by ROC curve 
analysis.
generation of linear discriminant functions
From the aforementioned 12 most significant vari-
ables,  9  became  the  input  variables  to  the  three 
  linear  discriminant  functions  (D1,  D2,  and  D3), 
which  we  were  able  to  generate  in  the  discovery micro-rNA diagnosis of colon cancer
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study {57 subjects [40 with CCA (stages II–IV) and 
17  NRM]}. Those  three  different  and  independent 
linear discriminant functions are the final diagnostic 
biomarker models. The D1 is a function of the follow-
ing 4 of the 9 aforementioned significant variables 
(miRNAs):
D1 = f (miR-182, miR-183, miR-30a-5p, TmiR-378)
  (1.1)
The letter ‘T’ preceding the name of a miRNA 
indicates that that miRNA variable was transformed 
in  order  to  meet  normality,  equality  of  variance, 
and/or equality of covariance requirements.
The D2 is a function of the following 3 of the 9 
aforementioned significant variables (mi RNAs):
D2 = f (miR-147, miR-182*, TmiR-30a-3p)  (1.2)
The D3 is a function of the following 4 of the 9 afore-
mentioned significant variables (miRNAs):
D3 = f (miR-137, miR-182, TmiR-224, TmiR-30a-3p)
  (1.3)
As can be seen from Equations (1.1), (1.2), and 
(1.3), the three linear discriminant functions D1, D2, 
and D3 are three different and independent functions. 
Table S1 (Supplementary Data) shows the exact D1, 
D2, and D3 functions. Table 1 shows the top 12 most 
significant  miRNAs,  including  the  9  miRNAs  that 
constitute the input variables to D1, D2, and D3 func-
tions,  along  with  their  ROC  AUC  rank,  relative 
expression, and other properties.
As was mentioned above, 9 of the 12 most signifi-
cant miRNA variables were employed to develop the 
D1, D2, and D3 functions. The remaining 3 miRNA 
variables were not employed due to high degree of 
multi collinearity, as well as due to inequality of 
covariance,  with  the  other  miRNA  variables.  For 
those same reasons, the D1, D2, and D3 functions 
with their respective miRNA variables represent the 
miRNA groups (out of the 12 most significant miRNA 
variables) that fulfilled all conditions required by 
discriminant  analysis.  Table  S2    (Supplementary 
Data) shows the test results for equality of covari-
ance and variance among the constituent miRNA 
variables of the D1, D2, and D3   functions. Table S3 
  (Supplementary Data) shows the test results for nor-
mality for the D1, D2, and D3   functions. We should 
point out here that, having lowered the criterion of 
significance (ROC AUC $ 0.90), we were able to 
generate several other discriminant functions, whose 
constituent miRNA variables were less significant 
than those employed by the D1, D2, and D3 func-
tions; but, following final assessment, they proved 
to be not as robust as the D1, D2, and D3, and they are 
consequently not presented here.
The D1, D2, and D3 functions that we generated are 
canonical linear discriminant functions; this means 
that  all  three  of  them,  by  definition,  are  centered 
at zero, i.e., the mean D1, D2, and D3 scores of the 
57 subjects used in the discovery study are all zero. 
In order to avoid having to deal with negative scores, 
especially in the case of the graphs, we centered all 
three discriminant functions at +20.
Computer programs
Computer  programs  were  written  using  MATLAB 
R2011b by The MathWorks, Inc., Natick, MA, USA.
Results
Discovery study
As was mentioned earlier, from the total number of 
96 subjects [68 with CCA (stages II–IV) and 28 NRM] 
used in this study, we randomly selected 57 subjects 
[40 with CCA (stages II–IV) and 17 NRM] for the 
development and training of the three diagnostic bio-
marker models (D1, D2, and D3); and we will hence-
forward refer to those 57 subjects as the 57 original 
subjects. After the development of the three diagnos-
tic biomarker models, we assessed their diagnostic 
accuracy using the aforementioned 57 original sub-
jects, which were employed for their development. 
This constitutes an important first step in the assess-
ment of a diagnostic test.
The cut-off score of the D1 diagnostic biomarker 
model, as well as those of the other two models, was 
determined by taking into account the results of the 
following two analyses: (1) calculation of the optimal 
point on the ROC curve based on the 57 scores of the 57 
original subjects used in the discovery study   [optimal 
point is defined as the point with the highest sensitiv-
ity and the lowest false positive rate   (1-specificity)] 
and (2) calculation of the 99.99%   confidence intervals Nikas and Low
4  Cancer Informatics 2012:11
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for the mean D1 scores of the two groups (CCA and 
NRM) and their respective standard deviations. Based 
on that, the cut-off score of the D1 model was deter-
mined to be 21.800. If a subject has a D1 score less 
than 21.800, then that subject is classified as a CCA; 
otherwise ($21.800), that subject is classified as an 
NRM. As can be seen from Figure 1, the D1 model 
correctly identified all (40/40) CCA subjects and all 
(17/17) NRM subjects. Since our target group is the 
CCA group, and since our reference group is the NRM 
group, it follows that, for the discovery study, the D1 
model exhibited a sensitivity = 40/40 = 1.000 and a 
specificity = 17/17 = 1.000. Figure 1 and Table  2A 
show all pertinent statistical results of the D1 diagnos-
tic biomarker model in connection with the discovery 
study in great detail.
The cut-off score of the D2 diagnostic biomarker 
model  was  determined  to  be  21.235.  If  a  sub-
ject has a D2 score less than 21.235, then that sub-
ject  is  classified  as  a  CCA;  otherwise  ($21.235), 
that  subject  is  classified  as  an  NRM.  As  can  be 
seen from Figure 1, the D2 model correctly identi-
fied all (40/40) CCA subjects and all (17/17) NRM 
subjects. Therefore, for the discovery study, the D2 
model exhibited a   sensitivity = 40/40 = 1.000 and a 
  specificity = 17/17 = 1.000. Figure 1 and Table 2A 
show all pertinent statistical results of the D2 diagnos-
tic biomarker model in connection with the discovery 
study in great detail.
Regarding  the  D3  diagnostic  biomarker  model, 
the  cut-off  score  was  determined  to  be  21.382.  If 
a subject has a D3 score less than 21.382, then that 
subject is classified as a CCA; otherwise ($21.382), 
that  subject  is  classified  as  an  NRM.  As  can  be 
seen from Figure 2, the D3 model correctly identi-
fied all (40/40) CCA subjects and all (17/17) NRM 
subjects. Therefore, for the discovery study, the D3 
model exhibited a sensitivity = 40/40 = 1.000 and a 
  specificity = 17/17 = 1.000. Figure 2 and Table 2A 
show all pertinent statistical results of the D3 diagnos-
tic biomarker model in connection with the discovery 
study in great detail.
Figure 3 shows the 3D scatter plot of the D1 vs. 
D2 vs. D3 scores of all 57 original subjects, provid-
ing, thus, a visual depiction of the diagnostic accu-
racy of all three models with respect to the discovery 
study. As can be seen, the two groups are segregated 
into  two  distinct  and  completely  separate  clusters: 
the CCA group (purple spheres) is at the front and 
lower level, whereas the NRM group (green spheres) 
is at the back and higher level. It can also be seen that 
there were no misclassifications by any of the three 
diagnostic models.
Validation study
As  was  mentioned  earlier,  from  the  total  number 
of  96  subjects  [68  with  CCA  (stages  II–IV)  and 
28 NRM] used in this study, we had randomly seg-
regated 39 subjects [28 with CCA (stages II–IV) and 
11 NRM] for the sole and express purpose of test-
ing our three diagnostic biomarker models. Those 39 
unknown subjects were completely extraneous to all 
three models, that is to say they were new and differ-
ent from the original 57 subjects used for the develop-
ment of the three models, and they had never before 
been encountered by any of the three models. This 
constitutes the most important test in the assessment 
of a diagnostic test.
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Figure 1. Scatter plot and bar graph of all 57 original subjects (40 CCA 
and 17 NrM) used in the Discovery Study in connection with the D1 and 
D2 diagnostic biomarker models. 
notes: As can be seen, 40/40 CCA subjects (purple color) had D1 and D2 
scores lower than the determined cut-off scores of 21.800 and 21.235, 
respectively; therefore, 40/40 CCA subjects were identified correctly by 
both D1 and D2 diagnostic biomarker models [sensitivity = 40/40 = 1.000 for 
both D1 and D2]. regarding the NrM group (green color), all 17 subjects 
had  D1  and  D2  scores  greater  than  the  determined  cut-off  scores  of 
21.800  and  21.235,  respectively;  therefore,  17/17  NrM  subjects  were 
identified  correctly  by  both  D1  and  D2  diagnostic  biomarker  models 
[specificity = 17/17 = 1.000 for both D1 and D2]. For the Discovery Study, 
the mean D1 and D2 scores of the 40 CCA subjects were18.4054 and 
18.3266 respectively (top of the D1 and D2 purple bars) and their respective 
standard deviations (whiskers above or below the top of the D1 and D2 
purple bars) were 1.0899 and 1.0703. The mean D1 and D2 scores of the 
17 NrM subjects were 23.7523 and 23.9373 respectively (top of the D1 and 
D2 green bars) and their respective standard deviations (whiskers above 
or below the top of the D1 and D2 green bars) were 0.7363 and 0.8029. 
The significance level was set at α = 0.001 (two-tailed), and the probability 
of significance for the D1 was P = 3.05 × 10−25 (independent t-Test with 
T-value = 18.4664), whereas the probability of significance for the D2 was 
P = 3.01 × 10−26 (independent t-Test with T-value = 19.3834). Both the D1 
and the D2 are parametrically distributed with respect to both groups.micro-rNA diagnosis of colon cancer
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Table 2. Statistical results of the three diagnostic biomarker models (D1, D2, and D3) in the Discovery Study (identification 
of the 57 original subjects) and in the Validation Study (identification of the 39 unknown subjects, which were new and dif-
ferent from the 57 original subjects). 
Diagnostic Test ROc AUc T-Value p ccA Group nRM Group
(2-tailed) [99.99% cI of mean] [99.99% cI of mean]
α = 0.001 (sD) (sD)
A (Discovery study)
D1 1.000 18.4664 3.05 × 10−25 [17.8457, 18.9607]
(1.0899)
[23.2097, 24.3414]
(0.7363)
D2 1.000 19.3834 3.01 × 10−26 [17.8040, 18.9029]
(1.0703)
[23.3861, 24.5940]
(0.8029)
D3 1.000 23.1476 4.96 × 10−30 [17.4960, 18.4864]
(0.9684)
[23.7995, 25.4473]
(1.0730)
ccA Group nRM Group
Mean ± sD Mean ± sD
B (Validation study)
D1 1.000 10.8991 4.17 × 10−13 18.5568 ± 1.4817 23.7912 ± 0.9013
D2 1.000 12.4374 8.76 × 10−15 18.5869 ± 1.1167 23.4817 ± 1.0766
D3 1.000 12.9987 2.30 × 10−15 18.1475 ± 1.2818 24.5298 ± 1.6149
notes: (A) The ROC AUC value, the T value and probability of significance (P) of the independent t-Test, the 99.99% confidence interval for the mean 
score of the CCA group and that of the NrM group, along with their respective standard deviations, of the D1, D2, and D3 diagnostic biomarker models 
in the Discovery Study are shown. (B) The ROC AUC value, the T value and probability of significance (P) of the independent t-Test, and the mean score 
of the CCA group and that of the NrM group, along with their respective standard deviations, of the D1, D2, and D3 diagnostic biomarker models in the 
Validation Study are shown. As can be seen, all six of those group mean scores, as observed in the validation study with the 39 unknown subjects, fall 
within the 99.99% confidence intervals of the respective group mean scores as predicted in the discovery study (A).
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Figure 2. Scatter plot and bar graph of all 57 original subjects (  40 CCA 
and 17 NrM) used in the Discovery Study in connection with the D3 diag-
nostic biomarker model. 
notes: As can be seen, 40/40 CCA subjects (purple color) had D3 scores 
lower than the determined cut-off score of 21.382; therefore, 40/40 CCA 
subjects were identified correctly by the D3 diagnostic biomarker model 
[sensitivity = 40/40 = 1.000].   regarding the NrM group (green color), all 
17 subjects had D3 scores greater than the determined cut-off score of 
21.382; therefore, 17/17 NRM subjects were identified correctly by the D3 
diagnostic biomarker model [  specificity = 17/17 = 1.000]. For the Discovery 
Study, the mean D3 score of the 40 CCA subjects was 18.0010 (top of the 
purple bar) and the standard deviation (whiskers above or below the top 
of the purple bar) was 0.9684. The mean D3 score of the 17 NrM subjects 
was 24.7016 (top of the green bar) and the standard deviation (whiskers 
above or below the top of the green bar) was 1.0730. The significance level 
was set at α = 0.001 (two-tailed), and the probability of significance for the 
D3 was P = 4.96 × 10−30 (independent t-Test with T-value = 23.1476). The 
D3 is parametrically distributed with respect to both groups.
As can be seen from Figures 4 and 5 and Table 2B, 
all three diagnostic biomarker models correctly diag-
nosed all of the 39 unknown subjects. More specifi-
cally, all 28 unknown CCA subjects had D1, D2, and D3 
scores that were less than the respective cut-off scores 
(21.800, 21.235, 21.382); whereas all 11 unknown NRM 
subjects had D1, D2, and D3 scores that were greater 
than  the  respective  aforementioned  cut-off  scores. 
  Therefore,  in  connection  with  the  validation  study, 
both the sensitivity and the specificity of all three diag-
nostic biomarker models were 1.000. Figure 6 shows 
the 3D scatter plot of the D1 vs. D2 vs. D3 scores of all 
39 unknown subjects, providing, thus, a visual depic-
tion of the diagnostic accuracy of all three models with 
respect to the validation study. As can be seen, the 39 
unknown subjects are segregated into two distinct and 
completely separate clusters: the CCA group (purple 
spheres) is at the front and lower level, whereas the 
NRM group (green spheres) is at the back and higher 
level. It can also be seen that there were no misclassifi-
cations by any of the three diagnostic models.
Table 2B, in addition to other pertinent statisti-
cal results of our three diagnostic biomarker models, 
shows the observed mean D1, D2, and D3 scores of Nikas and Low
8  Cancer Informatics 2012:11
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Figure 4. Scatter plot and bar graph of all 39 unknown (new and differ-
ent) subjects (28 CCA and 11 NrM) used in the Validation Study in con-
nection with the D1 and D2 diagnostic biomarker models. 
notes: As can be seen, 28/28 unknown CCA subjects (purple color) had 
D1 and D2 scores lower than the determined cut-off scores of 21.800 
and 21.235, respectively; therefore, 28/28 unknown CCA subjects were 
identified  correctly  by  both  D1  and  D2  diagnostic  biomarker  models 
[sensitivity = 28/28 = 1.000 for both D1 and D2]. regarding the NrM group 
(green color), all 11 unknown subjects had D1 and D2 scores greater 
than the determined cut-off scores of 21.800 and 21.235, respectively; 
therefore, 11/11 unknown NRM subjects were identified correctly by both 
D1 and D2 diagnostic biomarker models [specificity = 11/11 = 1.000 for 
both D1 and D2]. For the Validation Study, the mean D1 and D2 scores of 
the 28 unknown CCA subjects were 18.5568 and 18.5869 respectively 
(top of theD1 and D2 purple bars) and their respective standard deviations 
(whiskers above or below the top of the D1 and D2 purple bars) were 
1.4817 and 1.1167. The mean D1 and D2 scores of the 11 unknown NrM 
subjects were 23.7912 and 23.4817 respectively (top of the D1 and D2 
green bars) and their respective standard deviations (whiskers above or 
below the top of the D1 and D2 green bars) were 0.9013 and 1.0766. The 
significance level was set at α = 0.001 (two-tailed), and the probability 
of significance for the D1 was P = 4.17 × 10−13 (independent t-Test with 
T-value = 10.8991), whereas the probability of significance for the D2 was 
P = 8.76 × 10−15 (independent t-Test with T-value = 12.4374). Both the D1 
and the D2 are parametrically distributed with respect to both groups.
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Figure 5. Scatter plot and bar graph of all 39 unknown (new and   different) 
subjects (28 CCA and 11 NrM) used in the Validation Study in connec-
tion with the D3 diagnostic biomarker model. 
notes: As can be seen, 28/28 unknown CCA subjects (purple color) had 
D3 scores lower than the determined cut-off score of 21.382; therefore, 
28/28  unknown  CCA  subjects  were  identified  correctly  by  the  D3 
diagnostic biomarker model   [sensitivity = 28/28 = 1.000]. regarding the 
NrM group (green color), all 11 unknown subjects had D3 scores greater 
than the determined cut-off score of 21.382; therefore, 11/11 unknown 
NRM subjects were identified correctly by the D3 diagnostic biomarker 
model   [specificity = 11/11 = 1.000]. For the Validation Study, the mean D3 
score of the 28 unknown CCA subjects was 18.1475 (top of the purple 
bar) and the standard deviation (whiskers above or below the top of the 
purple bar) was 1.2818. The mean D3 score of the 11 unknown NrM 
subjects was 24.5298 (top of the green bar) and the standard deviation 
(whiskers above or below the top of the green bar) was 1.6149. The 
significance level was set at α = 0.001 (two-tailed), and the probability 
of significance for the D3 was P = 2.30 × 10−15 (independent t-Test with 
T-value = 12.9987). The D3 is parametrically distributed with respect to 
both groups.
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Figure 3. 3D Scatter plot of all 57 original subjects [40 CCA (purple) and 
17 NrM (green)] used in the Discovery Study in connection with the D1, 
D2, and D3 diagnostic biomarker models. 
notes: The D1, D2, and D3 scores of all 57 original subjects are plotted 
against each other (D1 vs. D2 vs. D3). As can be seen, there are two 
distinct, separate clusters: the purple one (CCA group) is at the front and 
at a lower level, whereas the green one (NrM group) is at the back and at 
a higher level. It can also be seen that there were no misclassifications.
the two groups (CCA and NRM) of the 39 unknown 
subjects. As can be seen, all six of those group mean 
scores, as observed in the validation study with the 39 
unknown subjects, fall within the 99.99% confidence 
intervals of the respective group mean scores as pre-
dicted in the discovery study (Table 2A).
Overall diagnostic biomarker model 
performance
If we combined the discovery study results with those 
of the validation study, then the overall performance 
of our three diagnostic biomarker models would be as 
follows. All three of them (D1, D2, and D3) exhibited an 
overall sensitivity = 1.000 (68/68 CCA   subjects) and 
an overall specificity = 1.000 (28/28 NRM subjects).
On the top 12 most significant miRNAs
In connection with the aforementioned 12 most sig-
nificant  miRNAs  identified  in  our  study,  we  con-
ducted an Ingenuity Pathway Analysis (IPA) search. 
We  sought  to  ascertain  information  about  those 
12 miRNAs pertaining to their known interactions 
with  genes;  their  known  interactions  with  drugs, micro-rNA diagnosis of colon cancer
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chemicals, and/or hormones; and their known asso-
ciations with various types of cancer as derived from 
the findings of scientific, peer-reviewed studies. The 
IPA search results are listed in Table 1, along with 
the direction of the statistically significant differential 
expression (over-expression or under-expression) of 
those 12 miRNAs in the CCA group relative to that of 
the NRM group. As can be seen from Table 1, nearly 
all of those 12 miRNAs are known to interact with 
genes, such as RASA1, TP53, CDK6, BCL10, EGR1, 
and RB1—genes that are involved in the regulation 
of oncogenesis.
Numerous miRNAs have been observed to be dif-
ferentially expressed in various types of cancer as 
compared with the normal healthy state. More spe-
cifically, miR-183 and miR-135b have been observed 
to be over-expressed in colon cancer cells as com-
pared to healthy tissue cells,8,9 and that agrees with 
our results (Table 1). Also in connection with colon 
cancer, miR-182* and miR-224 have been observed 
to  be  over-expressed,  whereas  miR-  30a-3p  and 
  miR-137 have been observed to be under-expressed;8 
those observations are also in agreement with our find-
ings (Table 1). In connection with colon cancer cell 
lines, miR-182 and miR-147 have been observed to 
be over-expressed and under-expressed, respectively;8 
and that also accords with the results of our analysis 
(Table 1). In the cases of hypopharyngeal squamous 
cell carcinoma and gastric cancer, miR-378 has been 
observed to be under-expressed,9,10 which is in agree-
ment with our findings. In the cases of prostate cancer 
and lung cancer, miR-30a-5p has been observed to 
be under-expressed,11,12 and that is also in agreement 
with our findings.
The original study by Sarver et al3 was an obser-
vational study. Using the criteria of P value and fold 
change,  the  authors  reported  over  forty  miRNAs 
that were determined to be differentially expressed 
between the subjects with colon cancer and the nor-
mal subjects. We should point out here that Sarver 
et al3 did not develop any diagnostic models (tests), 
much less validate them with unknown subjects that 
were  new  and  different  from  the  original  subjects 
and report the performance results of such diagnostic 
models (tests).
Discussion
Having employed 57 subjects [40 with CCA (stages   
II–IV) and 17 NRM], we were able to generate three 
different and independent linear discriminant functions,     
i.e.  three  different  and  independent  diagnostic  tests, 
that, based on the global miRNA analysis of tissue, can 
diagnose with perfect accuracy colon cancer.   Following 
validation with 39 unknown (new and   different) subjects 
[28 with CCA (stages II–IV) and 11 NRM], our three 
diagnostic tests (D1, D2, and D3) exhibited an overall 
sensitivity = 1.000 (68/68 CCA subjects) and an overall 
specificity = 1.000 (28/28 NRM subjects). This robust 
performance should be further tested using a wider pool 
of subjects in terms of   demographics, family history, 
and syndromic associations.
The clinical significance of our study is as follows. 
We were able to develop and independently validate 
three different and independent diagnostic tests that, 
based on the global miRNA analysis of tumor and 
healthy tissue, can discriminate with a perfect accu-
racy between subjects with colon cancer and normal 
subjects. The nine most significant miRNAs identi-
fied, which comprise the input variables to our three 
diagnostic  tests,  play,  therefore,  a  key  role  in  the 
development of colon cancer, as evidenced by the tis-
sue analysis. If an accurate and reliable detection and 
quantification of those nine key miRNAs were pos-
sible in the circulation (plasma or serum), then that 
would lead to early, accurate, and far less invasive 
diagnostic tests for colon cancer. Since early   detection 
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Figure 6. 3D Scatter plot of all 39 unknown (new and different) subjects 
[28 CCA (purple) and 11 NRM (green)] used in the Validation Study in 
connection with the D1, D2, and D3 diagnostic biomarker models. 
notes: The D1, D2, and D3 scores of all 39 unknown subjects are plotted 
against each other (D1 vs. D2 vs. D3). As can be seen, there are two 
distinct, separate clusters: the purple one (CCA group) is at the front and 
at a lower level, whereas the green one (NrM group) is at the back and at 
a higher level. It can also be seen that there were no misclassifications.Nikas and Low
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of colon cancer is associated with 91% survival,1 the 
results of our study may have a significant impact in 
the fight against this disease by contributing to the 
saving of thousands of lives of patients with colon 
cancer each year.
Detection of miRNAs in the circulation, be it in 
circulating  tumor  cells13  or  in  exosomes,14,15  has 
been demonstrated by numerous studies over the last 
several years. Circulating miRNAs have also been 
detected  in  connection  with  various  types  of  can-
cer, such as breast cancer,15 prostate cancer,16 liver 
cancer,17 esophageal cancer,18 etc. Therefore, identi-
fying and quantifying accurately and reliably, either 
in serum or in plasma, the aforementioned nine miR-
NAs that play a key role in the development of colon 
cancer constitutes the ultimate goal of this study.
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Table s1. Canonical linear discriminant functions of D1, 
D2, and D3 diagnostic biomarker models developed from 
the original 57 subjects [17 NRM (Group 0) and 40 CCA 
(group 1)]. 
Discriminant Analysis Report
group 0 1 Overall
Count 17 40 57
Variable canonical Variate
Canonical coefficients (D1)
Constant −18.363945
mir_182 −0.146842
mir_30a_5p 1.612585
mir_183 −0.609552
Tmir_378 0.000264
Canonical coefficients (D2)
Constant −0.360000
mir_182* −1.018370
mir_147 0.800789
Tmir_30a_3p 0.0000002
Canonical coefficients (D3)
Constant −16.476653
mir_182 −1.216682
mir_137 0.566376
Tmir_30a_3p 0.169121
Tmir_224 271.728594
notes: The constituent miRNA variables, their respective coefficients, 
and  the  constant  of  each  of  the  three  canonical  linear  discriminant 
functions (D1, D2, and D3) are shown. The letter ‘T’ preceding the name 
of a mirNA indicates that that mirNA variable was transformed in order 
to meet normality, equality of variance, and/or equality of covariance 
requirements.
supplementary TablesNikas and Low
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Table s2. Test results for equality of covariance and variance among the constituent mirNA variables of the D1, D2, and D3 
functions developed from the original 57 subjects [17 NRM (Group 0) and 40 CCA (Group 1)]. 
equality of covariance and Variance Report
group 0 1 Overall
Count 17 40 57
Variable Barlett F F chi2 chi2
Value DF1 DF2 Approx prob Approx prob
Bartlett-Box homogeneity tests (D1)
mir_182 0.8189 1 5517 0.80 0.371063 0.80 0.371148
mir_30a_5p 2.3170 1 5517 2.26 0.132402 2.26 0.132496
mir_183 0.2023 1 5517 0.20 0.656596 0.20 0.656644
Tmir_378 2.1038 1 5517 2.06 0.151640 2.05 0.151736
Box’s M 8.6511 10 4538 0.78 0.651808 7.78 0.649968
Bartlett-Box homogeneity tests (D2)
mir_182* 2.2110 1 5517 2.16 0.141599 2.16 0.141693
mir_147 0.1519 1 5517 0.15 0.700072 0.15 0.700114
Tmir_30a_3p 0.0523 1 5517 0.05 0.821247 0.05 0.821272
Box’s M 6.6653 6 6101 1.03 0.406328 6.16 0.405495
Bartlett-Box homogeneity tests (D3)
mir_182* 0.8189 1 5517 0.80 0.371063 0.80 0.371148
mir_137 0.0281 1 5517 0.03 0.868393 0.03 0.868412
Tmir_30a_3p 0.0523 1 5517 0.05 0.821247 0.05 0.821272
Tmir_224 2.3096 1 5517 2.26 0.133022 2.26 0.133116
Box’s M 14.9302 10 4538 1.34 0.202563 13.43 0.200457
notes: As can be seen from the probability of significance values of both the F and the χ2 tests for the Box’s M test, there are no statistically significant 
covariance differences among the constituent mirNA variables of the D1, D2, or D3 function. Likewise, the Bartlett test shows that there are no statistically 
significant variance differences among the constituent miRNA variables of the D1, D2, or D3 function.micro-rNA diagnosis of colon cancer
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Table s3. Normality test results for the D1, D2, and D3 linear discriminant functions with respect to both groups of the original 
57 subjects [17 NRM (Group 0) and 40 CCA (Group 1)] used for the development of the three functions. 
normality Tests Report
Test name Test value prob level 10% critical  
value
5% critical  
value
Decision (5%)
normality test section of D1 when Group = 0 (count 17)
Shapiro-Wilk W 0.9679477 0.7815679 Can’t reject normality
Anderson-Darling 0.3600979 0.4483844 Can’t reject normality
Martinez-lglewicz 1.135777 1.252524 1.438767 Can’t reject normality
Kolmogorov-Smirnov 0.1029178 0.19 0.207 Can’t reject normality
D’Agostino Skewness −0.6319371 0.527428 1.645 1.960 Can’t reject normality
D’Agostino Kurtosis 0.9578 0.338181 1.645 1.960 Can’t reject normality
D’Agostino Omnibus 1.3167 0.517716 4.605 5.991 Can’t reject normality
normality test section of D1 when Group = 1 (count 40)
Shapiro-Wilk W 0.9523966 9.170641e-02 Can’t reject normality
Anderson-Darling 0.4800356 0.233547 Can’t reject normality
Martinez-lglewicz 0.9609824 1.114676 1.175041 Can’t reject normality
Kolmogorov-Smirnov 0.0905983 0.126 0.139 Can’t reject normality
D’Agostino Skewness −0.3980126 0.6906209 1.645 1.960 Can’t reject normality
D’Agostino Kurtosis −2.4009 0.016356 1.645 1.960 reject normality
D’Agostino Omnibus 5.9226 0.051752 4.605 5.991 Can’t reject normality
normality test section of D2 when Group = 0 (count 17)
Shapiro-Wilk W 0.9018213 7.286435e-02 Can’t reject normality
Anderson-Darling 0.6532255 8.824592e-02 Can’t reject normality
Martinez-lglewicz 1.067013 1.252524 1.438767 Can’t reject normality
Kolmogorov-Smirnov 0.1256069 0.19 0.207 Can’t reject normality
D’Agostino Skewness −1.408385 0.159017 1.645 1.960 Can’t reject normality
D’Agostino Kurtosis −0.4372 0.661989 1.645 1.960 Can’t reject normality
D’Agostino Omnibus 2.1747 0.337114 4.605 5.991 Can’t reject normality
normality test section of D2 when Group = 1 (count 40)
Shapiro-Wilk W 0.9654804 0.2565536 Can’t reject normality
Anderson-Darling 0.4056016 0.3517282 Can’t reject normality
Martinez-lglewicz 1.038377 1.114676 1.175041 Can’t reject normality
Kolmogorov-Smirnov 7.907125e-02 0.126 0.139 Can’t reject normality
D’Agostino Skewness −1.585528 0.1128464 1.645 1.960 Can’t reject normality
D’Agostino Kurtosis 0.4021 0.687630 1.645 1.960 Can’t reject normality
D’Agostino Omnibus 2.6756 0.262427 4.605 5.991 Can’t reject normality
normality test section of D3 when Group = 0 (count 17)
Shapiro-Wilk W 0.9496766 0.4514251 Can’t reject normality
Anderson-Darling 0.3490809 0.4751235 Can’t reject normality
Martinez-lglewicz 1.136325 1.252524 1.438767 Can’t reject normality
Kolmogorov-Smirnov 0.1442362 0.19 0.207 Can’t reject normality
D’Agostino Skewness 1.580456 0.1140025 1.645 1.960 Can’t reject normality
D’Agostino Kurtosis 1.5018 0.133142 1.645 1.960 Can’t reject normality
D’Agostino Omnibus 4.7533 0.092860 4.605 5.991 Can’t reject normality
normality test section of D3 when Group = 1 (count 40)
Shapiro-Wilk W 0.9784388 0.6317195 Can’t reject normality
Anderson-Darling 0.2572377 0.7206884 Can’t reject normality
Martinez-lglewicz 0.9622557 1.114676 1.175041 Can’t reject normality
Kolmogorov-Smirnov 7.959955e-02 0.126 0.136 Can’t reject normality
D’Agostino Skewness 0.802801 0.4220898 1.645 1.960 Can’t reject normality
D’Agostino Kurtosis −0.6426 0.520487 1.645 1.960 Can’t reject normality
D’Agostino Omnibus 1.0574 0.589366 4.605 5.991 Can’t reject normality
note: As can be seen, D1, D2, and D3 are normally distributed with respect to both groups.publish with Libertas Academica and 
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